226 related articles for article (PubMed ID: 33142014)
1. Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults.
Min KC; Kraft WK; Bondiskey P; Colón-González F; Liu W; Xu J; Panebianco D; Mixson L; Dockendorf MF; Matthews CZ; Boinpally R
Clin Transl Sci; 2021 Mar; 14(2):599-605. PubMed ID: 33142014
[TBL] [Abstract][Full Text] [Related]
2. A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial.
Boinpally R; McNamee B; Yao L; Butler M; McGeeney D; Borbridge L; Periclou A
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1099-1107. PubMed ID: 33942560
[TBL] [Abstract][Full Text] [Related]
3. Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial.
Boinpally R; Jakate A; Butler M; Borbridge L; Periclou A
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):726-733. PubMed ID: 33501783
[TBL] [Abstract][Full Text] [Related]
4. Atogepant for the Preventive Treatment of Migraine.
Ailani J; Lipton RB; Goadsby PJ; Guo H; Miceli R; Severt L; Finnegan M; Trugman JM;
N Engl J Med; 2021 Aug; 385(8):695-706. PubMed ID: 34407343
[TBL] [Abstract][Full Text] [Related]
5. Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males.
Ankrom W; Bondiskey P; Li CC; Palcza J; Liu W; Dockendorf MF; Matthews C; Panebianco D; Reynders T; Wagner JA; Jakate A; Mesens S; Kraft WK; Marcantonio EE
Clin Transl Sci; 2020 May; 13(3):462-472. PubMed ID: 31899602
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial.
Tassorelli C; Nagy K; Pozo-Rosich P; Lanteri-Minet M; Sacco S; Nežádal T; Guo H; De Abreu Ferreira R; Forero G; Trugman JM
Lancet Neurol; 2024 Apr; 23(4):382-392. PubMed ID: 38364831
[TBL] [Abstract][Full Text] [Related]
7. Atogepant: First Approval.
Deeks ED
Drugs; 2022 Jan; 82(1):65-70. PubMed ID: 34813050
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults.
Goadsby PJ; Tepper SJ; Watkins PB; Ayele G; Miceli R; Butler M; Severt L; Finnegan M; Szegedi A; Trugman JM; Jakate A
Cephalalgia; 2019 Dec; 39(14):1753-1761. PubMed ID: 31537107
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.
Goadsby PJ; Dodick DW; Ailani J; Trugman JM; Finnegan M; Lu K; Szegedi A
Lancet Neurol; 2020 Sep; 19(9):727-737. PubMed ID: 32822633
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.
Ailani J; Lipton RB; Hutchinson S; Knievel K; Lu K; Butler M; Yu SY; Finnegan M; Severt L; Trugman JM
Headache; 2020 Jan; 60(1):141-152. PubMed ID: 31913519
[TBL] [Abstract][Full Text] [Related]
11. Atogepant (Qulipta) for migraine prevention.
Med Lett Drugs Ther; 2021 Nov; 63(1636):169-171. PubMed ID: 35085204
[No Abstract] [Full Text] [Related]
12. Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety.
Singh A; Balasundaram MK
Clin Drug Investig; 2022 Apr; 42(4):301-308. PubMed ID: 35230651
[TBL] [Abstract][Full Text] [Related]
13. Atogepant: an emerging treatment for migraine.
Rustichelli C; Avallone R; Ferrari A
Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319
[TBL] [Abstract][Full Text] [Related]
14. Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.
Lipton RB; Pozo-Rosich P; Blumenfeld AM; Dodick DW; McAllister P; Li Y; Lu K; Dabruzzo B; Miceli R; Severt L; Finnegan M; Trugman JM
JAMA Netw Open; 2022 Jun; 5(6):e2215499. PubMed ID: 35675076
[TBL] [Abstract][Full Text] [Related]
15. Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial.
Lipton RB; Nahas SJ; Pozo-Rosich P; Bilchik T; McAllister P; Finnegan M; Liu Y; Chalermpalanupap N; Dabruzzo B; Dodick DW
J Headache Pain; 2024 May; 25(1):83. PubMed ID: 38773375
[TBL] [Abstract][Full Text] [Related]
16. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
17. Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
Schwedt TJ; Lipton RB; Ailani J; Silberstein SD; Tassorelli C; Guo H; Lu K; Dabruzzo B; Miceli R; Severt L; Finnegan M; Trugman JM
Cephalalgia; 2022 Jan; 42(1):3-11. PubMed ID: 34521260
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
Lipton RB; Halker Singh RB; Mechtler L; McVige J; Ma J; Yu SY; Stokes J; Dabruzzo B; Gandhi P; Ashina M
Cephalalgia; 2023 Aug; 51(8):3331024231190296. PubMed ID: 37638400
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.
Tassorelli C; Onishchenko K; Halker Singh RB; Duan M; Dupont-Benjamin L; Hemstock M; Voller C; McAllister P; Nahas SJ; Gandhi P; Ailani J
Cephalalgia; 2024 Feb; 44(2):3331024241235156. PubMed ID: 38410850
[TBL] [Abstract][Full Text] [Related]
20. Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants.
Ankrom W; Xu J; Vallee MH; Dockendorf MF; Armas D; Boinpally R; Min KC
J Clin Pharmacol; 2020 Sep; 60(9):1157-1165. PubMed ID: 32297990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
